In final draft guidance published today we've confirmed that we’re unable to recommend cerliponase alfa (also called Brineura and made by BioMarin) for routine NHS use in treating neuronal ceroid ...

See a complete list of all our guidance and quality standards currently open for consultation ...

Hundreds of adults and teenagers in England with a rare, inherited eye disease will benefit from a new treatment after NICE today recommended idebenone for visual impairment caused by Leber's ...

Older people All NICE products on older people. Includes any guidance, advice and quality standards. Published products on this topic (21) ...

The treatment combines pembrolizumab, made by Merck Sharp & Dohme, with chemotherapy drugs carboplatin and paclitaxel. Pembrolizumab is an immunotherapy that helps the immune system recognise and ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England.

May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. For people with COPD see our guideline on diagnosing ...

Suggested remit: To appraise the clinical and cost effectiveness of idebenone within its marketing authorisation for treating visual impairment in Leber’s hereditary optic neuropathy (LHON) in people ...

Questions to ask about mental health problems in pregnancy and the year after birth These questions may help you discuss your condition or the treatments you have been offered with healthcare ...

NICE and the Medicines and Healthcare products Regulatory Agency (MHRA) have described how the 10-Year Health Plan will lead to faster medicines access for patients in the NHS in England. People ...

The following checklists are taken directly from the 'QUADAS-2' publication (Whiting PF Rutjes AWS, Westwood ME et al. and the QUADAS-2 group [2011] QUADAS-2: a revised tool for the quality assessment ...

This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by ...